Table of Contents Table of Contents
Previous Page  15 / 42 Next Page
Show Menu
Previous Page 15 / 42 Next Page
Page Background

• Atezolizumab was dosed at 1200 mg IV q3w in all cohorts

• Primary endpoint: Independent review facility (IRF)-assessed objective response rate (ORR) per RECIST v1.1

• Secondary endpoints:

• IRF-assessed progression-free survival (PFS) and

duration of response (DOR) per RECIST v1.1

• Investigator (INV)-assessed ORR, PFS and DOR

per RECIST v1.1 and modified RECIST

• Overall survival (OS)

• Safety

BIRCH: Phase II Trial of Atezolizumab Monotherapy

in PD-L1–Selected Advanced NSCLC



PD-L1 expression evaluated by IHC using the VENTANA SP142 assay.

IHC, immunohistochemistry; PD, progressive disease.

1. Peters S, et al.

J Clin Oncol

. 2017.

Carcereny et al., BIRCH. WCLC 2017


Cohort 1 (1L)

No prior chemo

n = 138

Cohort 2 (2L)

1 prior platinum chemo

n = 271

Cohort 3 (3L+)

≥ 2 prior chemos (including 1 platinum)

n = 254


Until loss of



• Locally advanced or

metastatic NSCLC

• Tumor PD-L1

expression by IHC


(TC2/3 and/or IC2/3)

• ECOG PS 0 or 1

• No brain metastases

N = 667

• Baseline PD-L1 expression was scored by IHC

in tumor cells (TC) as percentage of PD-L1

expressing TC and in tumor-infiltrating immune

cells (IC) as percentage of tumor area

• TC2/3 or IC2/3 = TC or IC ≥ 5%